Compare NSYS & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSYS | AEON |
|---|---|---|
| Founded | 1981 | N/A |
| Country | United States | United States |
| Employees | N/A | 8 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6M | 25.8M |
| IPO Year | 1996 | N/A |
| Metric | NSYS | AEON |
|---|---|---|
| Price | $12.25 | $0.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 15.7K | ★ 79.2K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,371,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.01 | N/A |
| 52 Week Low | $6.50 | $0.46 |
| 52 Week High | $15.39 | $1.45 |
| Indicator | NSYS | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 43.69 | 43.60 |
| Support Level | $8.62 | $0.82 |
| Resistance Level | $15.11 | $1.12 |
| Average True Range (ATR) | 0.96 | 0.07 |
| MACD | -0.26 | -0.01 |
| Stochastic Oscillator | 28.26 | 46.35 |
Nortech Systems Inc is a United States-based electronic manufacturing services company. It offers value-added engineering, technical, and manufacturing services and support, including project management, design, testing, prototyping, manufacturing, supply chain management, and post-market services. The company's manufacturing and engineering services include complete medical devices, printed circuit board assemblies, wire and cable assemblies, and complex higher-level electro-mechanical assemblies. It operates in the Medical, Aerospace, Defense, and Industrial markets, with key revenue coming from medical-related markets.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.